We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
Read MoreHide Full Article
Merck KGaA (MKGAF - Free Report) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
The company reports results under three business sectors – Healthcare, Life Science and Performance Materials. Strong performance at Life Science, which was the catalyst behind sales growth in the last few quarters, is anticipated to continue the trend in the to-be-reported quarter as well.
Merck KGaA’s share price has increased 4.4% year to date, while the Zacks classified Medical-Drugs industry gained 7.6%.
Sales at the Healthcare division are anticipated to be driven by products such as Erbitux, Gonal-f and Euthyrox. On Mar 2, the UK National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) for the use of Erbitux in combination with either Folfiri or Folfox as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC). This is a positive as now the patients can have access to this effective first-line treatment.
The Life Science division had witnessed solid organic sales growth last quarter driven by strong organic growth and synergies, and the integration of the Sigma-Aldrich business. This trend should continue in the fourth quarter as well.
For the Healthcare sector, the company is counting on its pharmaceutical pipeline and starting in 2017, aims to gain approval of one medicine or new indication every year.
Meanwhile, we expect management to shed light on Merck KGaA’s pipeline at the conference call.
Merck KGaA, in collaboration with Pfizer Inc. (PFE - Free Report) , is evaluating avelumab in several phase III studies for indications such as gastric cancer, platinum-resistant/refractory ovarian cancer, bladder cancer and advanced renal cell carcinoma. In Feb 2017, the companies announced that FDA accepted avelumab for Priority Review the Biologics License Application (BLA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Aug 27, 2017, for avelumab in this indication.
Here are a couple of health care stocks that you may want to consider, as our model shows that they have the right combination of elements – a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) – to post an earnings beat this quarter.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Bristol-Myers Squibb Company (BMY - Free Report) has an Earnings ESP of +5.41% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
Merck KGaA (MKGAF - Free Report) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
The company reports results under three business sectors – Healthcare, Life Science and Performance Materials. Strong performance at Life Science, which was the catalyst behind sales growth in the last few quarters, is anticipated to continue the trend in the to-be-reported quarter as well.
Merck KGaA’s share price has increased 4.4% year to date, while the Zacks classified Medical-Drugs industry gained 7.6%.
Sales at the Healthcare division are anticipated to be driven by products such as Erbitux, Gonal-f and Euthyrox. On Mar 2, the UK National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) for the use of Erbitux in combination with either Folfiri or Folfox as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC). This is a positive as now the patients can have access to this effective first-line treatment.
The Life Science division had witnessed solid organic sales growth last quarter driven by strong organic growth and synergies, and the integration of the Sigma-Aldrich business. This trend should continue in the fourth quarter as well.
For the Healthcare sector, the company is counting on its pharmaceutical pipeline and starting in 2017, aims to gain approval of one medicine or new indication every year.
Meanwhile, we expect management to shed light on Merck KGaA’s pipeline at the conference call.
Merck KGaA, in collaboration with Pfizer Inc. (PFE - Free Report) , is evaluating avelumab in several phase III studies for indications such as gastric cancer, platinum-resistant/refractory ovarian cancer, bladder cancer and advanced renal cell carcinoma. In Feb 2017, the companies announced that FDA accepted avelumab for Priority Review the Biologics License Application (BLA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Aug 27, 2017, for avelumab in this indication.
Merck KGaA Price and EPS Surprise
Merck KGaA Price and EPS Surprise | Merck KGaA Quote
Stocks that Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that they have the right combination of elements – a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) – to post an earnings beat this quarter.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
BioMarin Pharmaceutical Inc. (BMRN - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here
Bristol-Myers Squibb Company (BMY - Free Report) has an Earnings ESP of +5.41% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>